|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGuire WL, Horwitz KB, Pearson OH and
Segaloff A: Current status of estrogen and progesterone receptors
in breast cancer. Cancer. 39:(Suppl). S2934–S2947. 1977. View Article : Google Scholar
|
|
3
|
Dickson RB and Lippman ME: Estrogenic
regulation of growth and polypeptide growth factor secretion in
human breast carcinoma. Endocr Rev. 8:29–43. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuukasjärvi T, Kononen J, Helin H, Holli K
and Isola J: Loss of estrogen receptor in recurrent breast cancer
is associated with poor response to endocrine therapy. J Clin
Oncol. 14:2584–2589. 1996.PubMed/NCBI
|
|
5
|
Lück HJ and Roché H: Weekly paclitaxel: An
effective and well-tolerated treatment in patients with advanced
breast cancer. Crit Rev Oncol Hematol. 44:(Suppl). S15–S30. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sledge GW, Neuberg D, Bernardo P, Ingle
JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of
doxorubicin, paclitaxel, and the combination of doxorubicin and
paclitaxel as front-line chemotherapy for metastatic breast cancer:
An intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andre F and Pusztai L: Molecular
classification of breast cancer: Implications for selection of
adjuvant chemotherapy. Nat Clin Pract Oncol. 3:621–632. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buzdar A, Jonat W, Howell A, Jones SE,
Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, et
al: Arimidex Study Group: Anastrozole, a potent and selective
aromatase inhibitor, versus megestrol acetate in postmenopausal
women with advanced breast cancer: Results of overview analysis of
two phase III trials. J Clin Oncol. 14:2000–2011. 1996.PubMed/NCBI
|
|
10
|
Dombernowsky P, Smith I, Falkson G,
Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A,
Morgan M, et al: Letrozole, a new oral aromatase inhibitor for
advanced breast cancer: Double-blind randomized trial showing a
dose effect and improved efficacy and tolerability compared with
megestrol acetate. J Clin Oncol. 16:453–461. 1998.PubMed/NCBI
|
|
11
|
Lønning PE, Bajetta E, Murray R,
Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita
M, Aaronson NK, et al: Activity of exemestane in metastatic breast
cancer after failure of nonsteroidal aromatase inhibitors: A phase
II trial. J Clin Oncol. 18:2234–2244. 2000.PubMed/NCBI
|
|
12
|
Vergote I and Robertson JF: Fulvestrant is
an effective and well-tolerated endocrine therapy for
postmenopausal women with advanced breast cancer: Results from
clinical trials. Br J Cancer. 90:(Suppl 1). S11–S14. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dowsett M, Nicholson RI and Pietras RJ:
Biological characteristics of the pure antiestrogen fulvestrant:
Overcoming endocrine resistance. Breast Cancer Res Treat. 93:(Suppl
1). S11–S18. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Osborne CK, Wakeling A and Nicholson RI:
Fulvestrant: An oestrogen receptor antagonist with a novel
mechanism of action. Br J Cancer. 90:(Suppl 1). S2–S6. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Howell A: The future of fulvestrant
(‘Faslodex’). Cancer Treat Rev. 31:(Suppl 2). S26–S33. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen H, Liu J, Wang R, Qian X, Xu R, Xu T,
Li Q, Wang L, Shi Z, Zheng J, et al: Fulvestrant increases
gefitinib sensitivity in non-small cell lung cancer cells by
upregulating let-7c expression. Biomed Pharmacother. 68:307–313.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sui M, Huang Y, Park BH, Davidson NE and
Fan W: Estrogen receptor alpha mediates breast cancer cell
resistance to paclitaxel through inhibition of apoptotic cell
death. Cancer Res. 67:5337–5344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sui M, Jiang D, Hinsch C and Fan W:
Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing
estrogen receptor alpha to vinblastine and vinorelbine. Breast
Cancer Res Treat. 121:335–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang J, Sui M and Fan W: Estrogen
receptor α attenuates therapeutic efficacy of paclitaxel on breast
xenograft tumors. Breast Cancer Res Treat. 134:969–980. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang D, Sui M, Zhong W, Huang Y and Fan
W: Different administration strategies with paclitaxel induce
distinct phenotypes of multidrug resistance in breast cancer cells.
Cancer Lett. 335:404–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roepe PD: The P-glycoprotein efflux pump:
How does it transport drugs? J Membr Biol. 166:71–73. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sauna ZE, Kim IW and Ambudkar SV: Genomics
and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr.
39:481–487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: from genomics tomechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang D, Huang Y, Han N, Xu M, Xu L, Zhou
L, Wang S and Fan W: Fulvestrant, a selective estrogen receptor
down-regulator, sensitizes estrogen receptor negative breast tumors
to chemotherapy. Cancer Lett. 346:292–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu X, Sui M and Fan W: In vitro and in
vivo characterizations of tetrandrine on the reversal of
P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer
Res 25B. 1953–1962. 2005.
|
|
26
|
Duan Z, Choy E and Hornicek FJ: NSC23925,
identified in a high-throughput cell-based screen, reverses
multidrug resistance. PLoS One. 4:e74152009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren D, Zhu Q, Li J, Ha T, Wang X and Li Y:
Overexpression of angiopoietin-1 reduces doxorubicin-induced
apoptosis in cardiomyocytes. J Biomed Res. 26:432–438. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rebbaa A, Zheng X, Chou PM and Mirkin BL:
Caspase inhibition switches doxorubicin-induced apoptosis to
senescence. Oncogene. 22:2805–2811. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zuryń A, Litwiniec A, Gackowska L, Pawlik
A, Grzanka AA and Grzanka A: Expression of cyclin A, B1 and D1
after induction of cell cycle arrest in the Jurkat cell line
exposed to doxorubicin. Cell Biol Int. 36:1129–1135. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu R, Hilakivi-Clarke L and Clarke R:
Molecular mechanisms of tamoxifen-associated endometrial cancer
(Review). Oncol Lett. 9:1495–1501. 2015.PubMed/NCBI
|
|
31
|
Min CR, Kim MJ, Park YJ, Kim HR, Lee SY,
Chung KH and Oh SM: Estrogenic effects and their action mechanism
of the major active components of party pill drugs. Toxicol Lett.
214:339–347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Iqbal J, Ginsburg OM, Wijeratne TD, Howell
A, Evans G, Sestak I and Narod SA: Endometrial cancer and venous
thromboembolism in women under age 50 who take tamoxifen for
prevention of breast cancer: A systematic review. Cancer Treat Rev.
38:318–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Feng R and Dong L: Knockdown of
microRNA-127 reverses adriamycin resistance via cell cycle arrest
and apoptosis sensitization in adriamycin-resistant human glioma
cells. Int J Clin Exp Pathol. 8:6107–6116. 2015.PubMed/NCBI
|
|
34
|
Efferth T, Fabry U and Osieka R: Apoptosis
and resistance to daunorubicin in human leukemic cells. Leukemia.
11:1180–1186. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De U, Chun P, Choi WS, Lee BM, Kim ND,
Moon HR, Jung JH and Kim HS: A novel anthracene derivative, MHY412,
induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast
cancer cells through cell cycle arrest and downregulation of
P-glycoprotein expression. Int J Oncol. 44:167–176. 2014.PubMed/NCBI
|
|
36
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Llambi F and Green DR: Apoptosis and
oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet
Dev. 21:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bodley A, Liu LF, Israel M, Seshadri R,
Koseki Y, Giuliani FC, Kirschenbaum S, Silber R and Potmesil M: DNA
topoisomerase II-mediated interaction of doxorubicin and
daunorubicin congeners with DNA. Cancer Res. 49:5969–5978.
1989.PubMed/NCBI
|
|
39
|
Cirilli M, Bachechi F, Ughetto G, Colonna
FP and Capobianco ML: Interactions between morpholinyl
anthracyclines and DNA. The crystal structure of a morpholino
doxorubicin bound to d(CGTACG). J Mol Biol. 230:878–889. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kellogg GE, Scarsdale JN and Fornari FA
Jr: Identification and hydropathic characterization of structural
features affecting sequence specificity for doxorubicin
intercalation into DNA double-stranded polynucleotides. Nucleic
Acids Res. 26:4721–4732. 1998. View Article : Google Scholar : PubMed/NCBI
|
